Biosimilar Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F, Segmented by Product (Recombinant Non-glycosylated Proteins v/s Recombinant Glycosylated Proteins), By Technology (Mammalian v/s non-Mammalian), By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic & Autoimmune Disorders, Rheumatoid Arthritis, Others), By Region and Competition

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Global Biosimilar Contract Manufacturing Market is anticipated to witness an impressive growth during the forecast period. This can be ascribed to the growing prevalence of various chronic diseases. Additionally, increasing availability of cancer biosimilars with lowered prices and affordable treatment, along with the growing adoption of cost-effective healthcare systems across the globe, have increased the demand for biosimilar contract manufacturing. Additionally, growing geriatric population across the globe, susceptible to different kinds of chronic diseases, is further expected to increase the demand for biosimilar contract manufacturing, thereby fuelling the market growth through 2028. Besides, growing awareness on new therapy related to oncology and other chronic diseases is further expected to support the biosimilar contract manufacturing market during the forecast period. Furthermore, impending patent expiry of biological products alongside the launch of new biosimilars and increasing early entry of new players, are further expected to increase the demand for biosimilar contract manufacturing, thereby supporting the market growth. A total of 17 cancer or cancer-related biosimilar products have been approved by the US Food and Drug Administration since 2015.

Growing Prevalence of Chronic Disease is Propelling the Market’s Growth

The increasing incidence of diabetes and easy availability of biosimilars at lower costs over branded insulins are expected to drive the demand of insulin biosimilars’ adoption, thereby fuelling the market growth in the forecast period. The increasing demand for monoclonal antibodies is one of the major factors expected to boost the market growth. Furthermore, recombinant glycosylated protein biosimilars are used for the treatment of blood disorders, cancers, and infectious diseases. The most commonly occurring autoimmune disorders that can be treated by biosimilars are polyarticular spondylitis, plaque psoriasis, Crohn’s disease, and arthritis. These conditions are commonly treated with biosimilars such as adalimumab and etanercept, making them the most preferred therapy for autoimmune disorders. The high rate of these diseases is expected to increase the demand for biosimilars, thus boosting the market growth in the forecast period. In 2019, 37.3 million Americans, or 11.3% of the population, had diabetes. Nearly 1.9 million Americans have type 1 diabetes, including about 244,000 children and adolescents.

 

Increasing Contract Research Organizations Are Driving the Market’s Growth

The demand for contract manufacturing and services has been rapidly rising in the pharmaceutical market from the last few years. Some of the important Clinical Research Organizations (CRO) are IQVIA, Syneos Health, ICON and Parexel. Contract research and manufacturing organizations help the pharmaceutical companies in risk reduction, reduction in expenditures, aid in complex drug manufacturing process, and shorten the lead times. Additionally, the growing demand for novel drug discovery and the increasing number of clinical trials pertaining to research and development in the pharma industry are likely to enhance the CRO market share in future. Spain accounts for the sixth largest market for subsequent entry biologics in the European Union. The regulatory approval of biosimilars is likely to improve its demand in manufacturing and hence is expected to promote the market’s growth.

 


Download Free Sample Report


Market Segmentation

The global biosimilar contract manufacturing market can be segmented by product, by technology, by application, and by region. Based on product, the market can be divided into Recombinant Non-glycosylated Proteins v/s Recombinant Glycosylated Proteins. Based on technology, the market can be divided into Mammalian v/s non-Mammalian. Based on application, the market can be grouped into Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic & Autoimmune Disorders, Rheumatoid Arthritis, Others. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, United Kingdom dominated the global biosimilar contract manufacturing market on account of growing demand for lower cost therapy for the treatment chronic disease.

 

Market Players

Catalent, Inc., Boehringer Ingelheim GmbH, Alcami Corporation, Inc., Almac Group, Lonza Group AG, Biocon Limited, Avid Bioservice, Inc, Rentschler Biopharma SE, Fujifilm Kyowa Kirin Biologics Co., Ltd., WuXi Biologics, Inc. are some of the leading players operating in the Global Biosimilar Contract Manufacturing Market.


Recent Development

For instance, in August 2021, Samsung Biologics announced that it plans to invest USD 205 billion and hire more people to improve its CDMO business in biosimilar, and other things in the coming years. It will benefit several Samsung businesses, including Samsung Bioepis, which deals with biosimilars, and Samsung Biologics, which handles contract manufacturing.

For instance, in 2019, Shanghai HaiHe Biopharma Co. Ltd. raised USD 146.6 million as venture capital for its large cancer drug portfolio, which it shall utilize along with its outsourcing partner Zhejiang Jiuzhou Pharmaceutical Co., Ltd.

Attribute

Details

Base Year

2022

Historic Data

2018 – 2021

Estimated Year

2023

Forecast Period

2024 – 2028

Quantitative Units

Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered

·         By Product

·         By Technology

·         By Application

·         By Region

Regional scope

North America; Europe; Asia Pacific; South America; Middle East & Africa

Country scope

United States; Canada; Mexico; France; Germany; United Kingdom; Italy; Spain; China; India; Japan; South Korea; Australia; Brazil; Argentina; Colombia; South Africa; Saudi Arabia; UAE

Key companies profiled

Catalent, Inc., Boehringer Ingelheim GmbH, Alcami Corporation, Inc., Almac Group, Lonza Group AG, Biocon Limited, Avid Bioservice, Inc, Rentschler Biopharma SE, Fujifilm Kyowa Kirin Biologics Co., Ltd., WuXi Biologics, Inc.

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Report Scope:

In this report, global biosimilar contract manufacturing market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Biosimilar Contract Manufacturing Market, By Product:

o      Recombinant Non-glycosylated Proteins

o      Recombinant Glycosylated Proteins

·         Biosimilar Contract Manufacturing Market, By Technology:

o     Mammalian

o     Non-Mammalian

Biosimilar Contract Manufacturing Market, By Application:

o      Oncology

o      Blood Disorders

o      Growth Hormonal Deficiency

o      Chronic & Autoimmune Disorders

o      Rheumatoid Arthritis

o      Others

·         Biosimilar Contract Manufacturing Market, By Region:

o      North America

§  United States

§  Canada

§  Mexico

o      Europe

§  France

§  Germany

§  United Kingdom

§  Italy

§  Spain

o      Asia Pacific

§  China

§  India

§  Japan

§  South Korea

§  Australia

o      South America

§  Brazil

§  Argentina

§  Colombia

o      Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Biosimilar Contract Manufacturing Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Biosimilar Contract Manufacturing Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Service Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Biosimilar Contract Manufacturing Market Outlook

5.1.  Market Size & Forecast

5.1.1.     By Value

5.2.  Market Share & Forecast

5.2.1.     By Product (Recombinant Non-glycosylated Proteins v/s Recombinant Glycosylated Proteins)

5.2.2.     By Technology (Mammalian v/s non-Mammalian)

5.2.3.     By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic & Autoimmune Disorders, Rheumatoid Arthritis, Others)

5.2.4.     By Region

5.2.5.     By Company (2021)

5.3.  Market Map

5.3.1.     By Product

5.3.2.     By Technology

5.3.3.     By Application

5.3.4.     By Region

6.    North America Biosimilar Contract Manufacturing Market Outlook

6.1.  Market Size & Forecast          

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Product

6.2.2.     By Technology

6.2.3.     By Application

6.2.4.     By Country

6.3.  North America: Country Analysis

6.3.1.     United States Biosimilar Contract Manufacturing Market Outlook

6.3.1.1.         Market Size & Forecast

6.3.1.1.1.             By Value

6.3.1.2.         Market Share & Forecast

6.3.1.2.1.             By Product

6.3.1.2.2.             By Technology

6.3.1.2.3.             By Application

6.3.2.     Canada Biosimilar Contract Manufacturing Market Outlook

6.3.2.1.         Market Size & Forecast

6.3.2.1.1.             By Value

6.3.2.2.         Market Share & Forecast

6.3.2.2.1.             By Product

6.3.2.2.2.             By Technology

6.3.2.2.3.             By Application

6.3.3.     Mexico Biosimilar Contract Manufacturing Market Outlook

6.3.3.1.         Market Size & Forecast

6.3.3.1.1.             By Value

6.3.3.2.         Market Share & Forecast

6.3.3.2.1.             By Product

6.3.3.2.2.             By Technology

6.3.3.2.3.             By Application

7.    Europe Biosimilar Contract Manufacturing Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Product

7.2.2.     By Technology

7.2.3.     By Application

7.2.4.     By Country

7.3.  Europe: Country Analysis

7.3.1.     France Biosimilar Contract Manufacturing Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Product

7.3.1.2.2.             By Technology

7.3.1.2.3.             By Application

7.3.2.     Germany Biosimilar Contract Manufacturing Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Product

7.3.2.2.2.             By Technology

7.3.2.2.3.             By Application

7.3.3.     United Kingdom Biosimilar Contract Manufacturing Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Product

7.3.3.2.2.             By Technology

7.3.3.2.3.             By Application

7.3.4.     Italy Biosimilar Contract Manufacturing Market Outlook

7.3.4.1.         Market Size & Forecast

7.3.4.1.1.             By Value

7.3.4.2.         Market Share & Forecast

7.3.4.2.1.             By Product

7.3.4.2.2.             By Technology

7.3.4.2.3.             By Application

7.3.5.     Spain Biosimilar Contract Manufacturing Market Outlook

7.3.5.1.         Market Size & Forecast

7.3.5.1.1.             By Value

7.3.5.2.         Market Share & Forecast

7.3.5.2.1.             By Product

7.3.5.2.2.             By Technology

7.3.5.2.3.             By Application

8.    Asia-Pacific Biosimilar Contract Manufacturing Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Product

8.2.2.     By Technology

8.2.3.     By Application

8.2.4.     By Country

8.3.  Asia-Pacific: Country Analysis

8.3.1.     China Biosimilar Contract Manufacturing Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Product

8.3.1.2.2.             By Technology

8.3.1.2.3.             By Application

8.3.2.     India Biosimilar Contract Manufacturing Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Product

8.3.2.2.2.             By Technology

8.3.2.2.3.             By Application

8.3.3.     Japan Biosimilar Contract Manufacturing Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Product

8.3.3.2.2.             By Technology

8.3.3.2.3.             By Application

8.3.4.     South Korea Biosimilar Contract Manufacturing Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Product

8.3.4.2.2.             By Technology

8.3.4.2.3.             By Application

8.3.5.     Australia Biosimilar Contract Manufacturing Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Product

8.3.5.2.2.             By Technology

8.3.5.2.3.             By Application

9.    South America Biosimilar Contract Manufacturing Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Product

9.2.2.     By Technology

9.2.3.     By Application

9.2.4.     By Country

9.3.  South America: Country Analysis

9.3.1.     Brazil Biosimilar Contract Manufacturing Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Product

9.3.1.2.2.             By Technology

9.3.1.2.3.             By Application

9.3.2.     Argentina Biosimilar Contract Manufacturing Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Product

9.3.2.2.2.             By Technology

9.3.2.2.3.             By Application

9.3.3.     Colombia Biosimilar Contract Manufacturing Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Product

9.3.3.2.2.             By Technology

9.3.3.2.3.             By Application

10.  Middle East and Africa Biosimilar Contract Manufacturing Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Product

10.2.2.  By Technology

10.2.3.  By Application

10.2.4.  By Country

10.3.              MEA: Country Analysis

10.3.1.  South Africa Biosimilar Contract Manufacturing Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Product

10.3.1.2.2.           By Technology

10.3.1.2.3.           By Application

10.3.2.  Saudi Arabia Biosimilar Contract Manufacturing Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Product

10.3.2.2.2.           By Technology

10.3.2.2.3.           By Application

10.3.3.  UAE Biosimilar Contract Manufacturing Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Product

10.3.3.2.2.           By Technology

10.3.3.2.3.           By Application

11.  Market Dynamics

11.1.              Drivers

11.2.              Challenges

12.  Market Trends & Developments

13.  Competitive Landscape

13.1.              Business Overview

13.2.              Product Offerings

13.3.              Recent Developments

13.4.              Financials (As Reported)

13.5.              Key Personnel

13.6.              SWOT Analysis

13.6.1.  Catalent, Inc.

13.6.2.  Boehringer Ingelheim GmbH

13.6.3.  Alcami Corporation, Inc.

13.6.4.  Almac Group

13.6.5.  Lonza Group AG

13.6.6.  Biocon Limited

13.6.7.  Avid Bioservice, Inc

13.6.8.  Rentschler Biopharma SE

13.6.9.  Fujifilm Kyowa Kirin Biologics Co., Ltd.

13.6.10.                WuXi Biologics, Inc.

Strategic Recommendations

Figures and Tables

Frequently asked questions

down-arrow

Increasing prevalence of chronic diseases like cancer, diabetes, neurological disorder, and rising demand for lower cost therapy are some of the major factors driving the growth of global biosimilar contract manufacturing market.

down-arrow

Catalent, Inc., Boehringer Ingelheim GmbH, Alcami Corporation, Inc., Almac Group, Lonza Group AG, Biocon Limited, Avid Bioservice, Inc, Rentschler Biopharma SE, Fujifilm Kyowa Kirin Biologics Co., Ltd., WuXi Biologics, Inc. are some of the leading players operating in the Global Biosimilar Contract Manufacturing Market.

down-arrow

The recombinant non glycosylated proteins are expected to dominate the global biosimilar contract manufacturing market during the forecast period.

down-arrow

North American region is expected to hold the largest share in the Global Biosimilar Contract Manufacturing Market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Biosimilar Contract Manufacturing Market to be dominated by Recombinant Non-Glycosylated Proteins Type through 2028

Dec, 2022

Increasing chronic disease is expected to drive the growth of global biosimilar contract manufacturing in the forecast period, 2024-2028.

Why Choose Us